Switching GLP-1 Medications: What to Expect When You Change

Switching GLP-1 medications is common — driven by insurance changes, supply, side effects, or a plateau. But because semaglutide and tirzepatide aren’t interchangeable milligram-for-milligram, a switch isn’t as simple as picking up where you left off. Here’s what to expect, and why this is firmly a prescriber-led decision.

Why people switch

• Insurance and coverage. A plan changes what it covers, or a prior authorization lands on the other drug. This is probably the most common reason.
• Supply. Shortages push people toward whatever’s available.
• Results. A plateau at a maxed dose sometimes prompts a move from semaglutide to tirzepatide, which produced larger average loss in trials (and beat semaglutide head-to-head in SURMOUNT-5).
• Side effects. Occasionally one molecule is tolerated better than the other.
• Coming off compounded to a brand-name product as shortages resolve.

The key fact: doses don’t map 1:1

You cannot assume “I was on 1 mg semaglutide, so I’ll start at the equivalent tirzepatide.” They’re different molecules with different dosing scales, and there’s no clean conversion. In practice, prescribers usually restart the new medication at or near its starting dose and re-titrate — sometimes a bit faster if you’ve clearly tolerated the class, but often from the bottom.

That can feel like a step backward, and it has a real consequence: the early titration side effects can return with the new drug, because your tolerance was built for the old molecule, not this one. Expect a possible repeat of the week-1 experience, and plan the switch for a lower-stress stretch if you can.

Semaglutide ↔ tirzepatide, briefly

• Semaglutide → tirzepatide (e.g. Wegovy → Zepbound): often chosen for stronger results; you’ll typically restart tirzepatide’s ladder from 2.5 mg.
• Tirzepatide → semaglutide (e.g. Zepbound → Wegovy): often coverage-driven; restart semaglutide’s ladder, usually from 0.25 mg.

The gap in timing matters too — if there’s a break between the old and new prescriptions, treat the restart like restarting after any break, where tolerance may have reset.

What to track through a switch

A switch is exactly when a good record pays off:

• Where you left off — your last dose and date on the old drug.
• How the new titration feels — side effects against each new step, so you and your prescriber can tell “normal re-adaptation” from “too fast.”
• Appetite and weight trend across the change — did the new molecule hold appetite as well, better, or worse? This is genuinely useful data, since response to each drug varies person to person.

Keeping your dose history continuous across the switch (Glu tracks any medication, so the timeline doesn’t reset) means the comparison is there when you need it.

The bottom line

Switching is routine, but it’s a medical decision about non-interchangeable drugs — not a swap you engineer yourself. Let your prescriber set the starting dose and titration, expect a possible return of early side effects, and track the transition so the change is guided by your data rather than guesswork.

Sources: SURMOUNT-5 head-to-head trial (2025); Wegovy and Zepbound prescribing information (dosing and titration).